Back to News
Market Impact: 0.4

Zealand Pharma's short bowel syndrome drug wins backing from EU panel

Source: reuters.com

Healthcare & BiotechRegulation & Legislation
Zealand Pharma's short bowel syndrome drug wins backing from EU panel

Zealand Pharma received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending approval of Zeydovio for short bowel syndrome. The recommendation is a significant regulatory milestone and improves the likelihood of eventual European commercialization for the drug candidate.

AllMind Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Trial

Market Sentiment

Overall Sentiment

strongly positive

Sentiment Score

0.72

Ticker Sentiment

ZEAL0.82

More News

From AllMind Research

Browse all research